SCHEMBL1097431

SCHEMBL1097431

NC(=O)c1nccnc1N

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 6/20 0.48
ATR Q13535 1/20 0.48
GRM5 P41594 1/20 0.46
TLR7 Q9NYK1 3/20 0.42
PDPK1 O15530 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
TSHR P16473 1/20 0.41
MC4R P32245 1/20 0.41
ADRA1A P35348 1/20 0.41
MC3R P41968 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
GDA Q9Y2T3 1/20 0.40
NAPRT Q6XQN6 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GBA1 P04062 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30065824 1.00 PRKCI (0.48) PRKCIATRGRM5TLR7PDPK1
SCHEMBL2492969 0.84 TSHR (0.48) PRKCIATRGRM5PDPK1ADORA3
SCHEMBL27669301 0.82 PRKCI (0.50) PRKCIATRGRM5TLR7NAPRT
SCHEMBL65106 0.80 ATR (0.53) PRKCIATRGRM5TLR7TSHR
SCHEMBL20853598 0.80 PRKCI (0.48) PRKCIATRGRM5TLR7NAPRT
SCHEMBL29578557 0.80 ATR (0.53) PRKCIATRGRM5TLR7TSHR
SCHEMBL3292931 0.78 PRKCI (0.47) PRKCIATRGRM5TLR7NAPRT
SCHEMBL30504248 0.78 PRKCI (0.47) PRKCIATRGRM5TLR7NAPRT
Hydrochloric Acid SCHEMBL29522091 0.78 ATR (0.52) PRKCIATRGRM5TLR7TSHR
SCHEMBL4569355 0.78 PRKCI (0.47) PRKCIATRGRM5TLR7NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145483-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME HTG MOLECULAR DIAGNOSTICS, INC. (US) 2024-07-04 WO claimed
CN-117024413-B 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof 天津匠新致成科技有限公司 2024-01-09 CN claimed
CN-117003736-B 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof 天津匠新致成科技有限公司 2023-12-15 CN claimed
CN-117024413-A 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof 天津匠新致成科技有限公司 2023-11-10 CN claimed
CN-117003736-A 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof 天津匠新致成科技有限公司 2023-11-07 CN claimed
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2022-11-17 US claimed
CN-112654609-A Amino-pyrazine carboxamide compounds, conjugates and uses thereof 希沃尔拜克治疗公司 2021-04-13 CN claimed
CN-106699759-B A kind of pteridine derivatives and contain its pharmaceutical composition 李柱来 2019-07-19 CN claimed
CN-106699759-A Pteridine derivative and pharmaceutical composition containing same 李柱来 2017-05-24 CN claimed
EP-2038264-B1 TETRAZOLE-SUBSTITUTED ARYLAMIDES HOFFMANN LA ROCHE (CH) 2016-10-26 EP claimed
CN-100546580-C Nicotine or nicotimine benzothiazole derivant HOFFMANN LA ROCHE (CH) 2009-10-07 CN claimed
CN-1617722-A Nicotin-or isonicotin benzothiazole derivatives HOFFMANN LA ROCHE (CH) 2005-05-18 CN claimed
EP-0399856-B1 Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them LIPHA (FR) 1995-08-09 EP claimed
US-5167949-A Antiallergic LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1992-12-01 US claimed
EP-0399856-A1 Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1990-11-28 EP claimed
JP-2304089-A None JP disclosed
CN-122121515-A Multifunctional organic additive doped CsSnI3Preparation and application of perovskite film 2026-05-29 CN disclosed
JP-H02304089-A 4(3H)-PTERIDINONE, ITS PRODUCTION, ANTIALLERGIC AGENT AND BRONCHOCONSTRICTION PREVENTIVE LIPHA (LYON IND PHARMACEUT) 1990-12-17 JP disclosed
EP-0399856-A1 Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1990-11-28 EP disclosed
US-4361700-A DIURETICS Waldron, James S. (US) 1982-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF TGFBR2, SMAD2, ACVR2A PRKCI 4024/4885ATR 2222/4885GRM5 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.